Navigation Links
BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
Date:11/5/2009

LYNBROOK, N.Y., Nov. 5 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products, today announced its financial results for the third quarter ended September 30, 2009.

"We were extremely happy that, in September of this year, the FDA's Arthritis Advisory Committee unanimously recommended, by a vote of 12-0, the approval of XIAFLEX(TM) for the treatment of Dupuytren's disease, and we are eagerly awaiting a response on the Biologics License Application that was submitted by our partner, Auxilium," stated Thomas L. Wegman, President of BioSpecifics. "We also look forward to the Phase IIb results testing XIAFLEX in Peyronie's disease, which Auxilium expects to report in December."

"I am very pleased that for the nine months ended September 30, 2009, as compared to the nine months ended September 30, 2008, Company revenues increased by 100% and, during the same period, the Company's net loss decreased," continued Mr. Wegman.

Three Months Ended September 30, 2009 and 2008

The Company reported a net loss of $0.4 million for the third quarter ended September 30, 2009, or ($0.06) per basic and diluted common share, compared to a net loss of $0.2 million, or ($0.04) per basic and diluted common share, for the same period in 2008.

Revenue for the third quarter ended September 30, 2009 was $0.8 million, compared to $0.3 million for the same period in 2008. The increase in revenue was due to earn-out payments triggered by certain net sales levels of topical collagenase under the earn-out payment provision of the Company's Asset Purchase Agreement with DFB Biotech, Inc.

Research and development expenses for the third quarter ended September 30, 2009 and 2008 were approximately $0.1 million in
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. BioSpecifics to Present at the 9th Annual Healthcare Conference of Acumen Bio Fin Rodman Renshaw LLC
2. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
3. BioSpecifics Technologies Corp. Announces Repayment of Outstanding Loan
4. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
5. BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering
6. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
7. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
8. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
9. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
10. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
11. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... , Health care employmen...emains the only one to show consistent growth duri...lty hospitals remain in trouble, and health system...cal personnel, instead of just administrators. , ...-- Health care employment continued growing in Oct...
(Date:11/24/2009)... ,, SEATTLE,Nov.24/PRNewswire/--BlueMarbleEn...ublicDevelopmentAuthority(OPDA)wererecentlyawarded...alizationBoard(CERB)inaprivate/publicpartnershipto...ineryinLincolnCounty,WA. ,, "Thisinvestmentwill...dbringover70greenjobstoLincolnCounty,"saidBlueMarb...
(Date:11/24/2009)... ,, SANDIEGO,Nov.24,2009/PRNewswire-FirstCal...ced todaythatthecompanyisscheduledtopresentattheP...r1,2009at11:30a.m.EasternTime(8:30a.m.PacificTime)...a,s President andChiefExecutiveOfficer,isscheduled...aldevelopmentanddiscoveryprograms. ,, Aliveaudi...
(Date:11/24/2009)... ,, SEATTLE,Nov.24/PRNewswire-FirstCall/--Ce...entwillpresentatthe21stAnnualPiperJaffrayHealthCar...9,attheNewYorkPalaceHotel. ,, CTIwillpresentonT...hFloor).AliveaudiowebcastofCTI,spresentationwillbe...obeavailableforreplayafterwards. , ,PiperJaffrayH...
Breaking Biology Technology:The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2
...nsional liquid chromatography (MDLC) • revers...MS/MS • DeCyder MS • differential analys...n conjunction with tandem mass spectrometry (MS/MS...racted from the pollen of the olive tree, Olea eu...oftware (DeCyder MS) was used to quantitate differ...
... DNA Genotek Inc., Ottawa, ON, Canada , ...l with TaqMan SNP Genotyping Assays. , SN...n E genes were reliably , detected., ...nucleotide polymorphisms (SNPs) are highly abundan...of every 1,000 bases in the human genome (ref. 1)....
... Ottawa, Ontario, Canada , , St...n add significant , costs to a project. O..., specimens to be stored for years at room..., , Introduction , L...to thousands of subjects, , are frequentl...
Other Biology Technology:Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 2Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 3Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 4Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 5Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 6Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 7Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 8Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 9Oragene is compatible with TaqMan SNP genotyping 2Oragene is compatible with TaqMan SNP genotyping 3DNA Stability with Oragene 2DNA Stability with Oragene 3
(Date:11/23/2009)... CHAMPAIGN, Ill. A new study provides "incontrov... of Toba on the island of Sumatra about 73,000 yea...0 miles from the epicenter, researchers report. ,...eters of ash into the atmosphere, leaving a crater...00 kilometers long and 35 kilometers wide. Ash fro...
(Date:11/23/2009)..., BIRMINGHAM, Ala. A new study by University of...t body-mass index (BMI) and co-existing medical co...ed survival observed among African-Americans compa...study is published online Nov. 23 in Cancer , a j...ding indicates that although BMI and co-morbidity ...
(Date:11/23/2009)...CORVALLIS, Ore. A string of recent discoveries ab...renewed interest in this multi-purpose nutrient, i...ho are deficient in it, spurred research and even ...ic." , On issues ranging from the health of your...even vulnerability to influenza, vitamin D is now ...
Breaking Biology News(10 mins):Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2Racial disparity in colon cancer survival not easily explained, UAB researchers say 2Multiple health concerns surface as winter, vitamin D deficiences arrive 2Multiple health concerns surface as winter, vitamin D deficiences arrive 3Diamyd 28R 29 Phase III Study Approved for Younger Patients in the US 12511 1Diamyd 28R 29 Phase III Study Approved for Younger Patients in the US 12511 2Photos 3A FDA Approves 12 Month Labeling Update for EVOLENCE 28R 29 Collagen Based Facial Filler 12508 1Photos 3A FDA Approves 12 Month Labeling Update for EVOLENCE 28R 29 Collagen Based Facial Filler 12508 2Photos 3A FDA Approves 12 Month Labeling Update for EVOLENCE 28R 29 Collagen Based Facial Filler 12508 3Photos 3A FDA Approves 12 Month Labeling Update for EVOLENCE 28R 29 Collagen Based Facial Filler 12508 4Somanetics Corporation to Release Second Quarter 2009 Financial Results and Host Conference Call June 17 2009 48147 1Somanetics Corporation to Release Second Quarter 2009 Financial Results and Host Conference Call June 17 2009 48147 2
...covery that sheds new light upon the growth and de...rful but somewhat mysterious components of the bod...se against cancer and infectious diseases. , Scien...are generated in bone marrow, but Michael Caligiur... and the senior author of the study, says research...
...ntific world has accepted for more than 100 years,...eir grandparents, bypassing genetic abnormalities ...nts apparently have hidden templates containing ge...at can be transferred to their offspring, even tho...rding to Purdue University researchers. This disco...
... severe malaria before they reach hospital, has th... this week,s BMJ. , Every year over a million chi...talities occur outside hospital, especially in rur...lf of deaths occur within 24 hours of admission. ,...t possible to administer outside hospital, so buyi...
Other Biology News:Scientists identify new model Of NK cell development 2Scientists identify new model Of NK cell development 3Plants defy Mendel's inheritance laws, may prompt textbook changes 2Plants defy Mendel's inheritance laws, may prompt textbook changes 3
Yeast-GFP 96-well Plates from Invitrogen
...joined forces with the Mickle Laboratory Engineeri...hopper. This tissue sectioning system has been des...experiments and to be especially applicable to sma...from small organs. Its special features cause much...
Earle's Balanced Salt Solution, 10x (EBSS) from Sigma-Aldrich
...ive peptides are molecules of peptidic nature or o...vity which can be developed at the industrial leve...o-food applications. In this way it is possible to... for therapeutic applications. Primm offers a desi...
Biology Products: